GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List

Latest Data & Signals Issued

Signal Type Signal Value Data
Score 0.000 59 days ( 0 % )
Last Price $0.0500 0 %
High/ Low $0.0500 - $0.0500 0%
Chg 7 Days N/A $0.0500 $0.0500
Chg 30 Days N/A $0.0500 $0.0500
Chg 12 mos -98.41 % $3.15 $0.0500
Trend - 3 mos N/A Width: 0.00000000 %
Trend - 12 mos -88.97 % Width: 124.11 %
Pred. range - 3 mos $0.0500 - $0.0500 0 % - 0 %
Pred. range - 12 mos N/A - $0.0329 -100.00 % - -34.17 %
Short MA avg 3 mos Sell 0000-00-00 - N/A days
Long MA avg 3 mos Sell 0000-00-00 - N/A days
Short/Long MA avg 3 mos Sell 0000-00-00 - N/A days
Short MA avg 12 mos Buy 2023-10-12 - 98 days
Long MA avg 12 mos Sell 2023-06-16 - 178 days
Short/Long MA avg 12 mos Sell 2023-06-02 - 188 days
Pivot Short Buy 2024-03-01 - 2 days
Bollinger Sell 0000-00-00 - N/A days
MACD N/A No Dates Stored For This Signal
Click to get the best stock tips daily for free!

About ContraFect Corporation

ContraFect ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the in... CFRX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT